Log In
Print
BCIQ
Print
Print this Print this
 

Px-102

  Manage Alerts
Collapse Summary General Information
Company Phenex Pharmaceuticals AG
DescriptionNon-steroidal farnesoid X receptor (FXR) agonist
Molecular Target Farnesoid X receptor (FXR) (NR1H4)
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationNon-alcoholic steatohepatitis (NASH)
Indication DetailsTreat non-alcoholic steatohepatitis (NASH)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$470.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today